Raiffeisen Bank International AG Makes New $815,000 Investment in PROCEPT BioRobotics Corporation $PRCT

Raiffeisen Bank International AG acquired a new stake in shares of PROCEPT BioRobotics Corporation (NASDAQ:PRCT) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 14,000 shares of the company’s stock, valued at approximately $815,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Osterweis Capital Management Inc. boosted its position in shares of PROCEPT BioRobotics by 98.0% in the first quarter. Osterweis Capital Management Inc. now owns 173,735 shares of the company’s stock worth $10,122,000 after purchasing an additional 85,990 shares during the period. Lisanti Capital Growth LLC bought a new stake in shares of PROCEPT BioRobotics during the 2nd quarter valued at $2,532,000. Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in shares of PROCEPT BioRobotics by 109.3% during the 2nd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 159,874 shares of the company’s stock valued at $9,209,000 after buying an additional 83,498 shares in the last quarter. Millennium Management LLC boosted its holdings in PROCEPT BioRobotics by 88.6% in the 1st quarter. Millennium Management LLC now owns 542,987 shares of the company’s stock worth $31,634,000 after buying an additional 255,140 shares during the period. Finally, Blair William & Co. IL boosted its holdings in PROCEPT BioRobotics by 5.7% in the 2nd quarter. Blair William & Co. IL now owns 497,205 shares of the company’s stock worth $28,639,000 after buying an additional 26,919 shares during the period. 89.46% of the stock is owned by hedge funds and other institutional investors.

PROCEPT BioRobotics Stock Performance

NASDAQ:PRCT opened at $28.40 on Wednesday. The company has a market cap of $1.59 billion, a price-to-earnings ratio of -18.56 and a beta of 0.98. PROCEPT BioRobotics Corporation has a 1 year low of $28.28 and a 1 year high of $100.89. The stock’s 50 day simple moving average is $34.74 and its two-hundred day simple moving average is $46.39. The company has a debt-to-equity ratio of 0.14, a current ratio of 8.44 and a quick ratio of 7.20.

PROCEPT BioRobotics (NASDAQ:PRCT) last posted its earnings results on Tuesday, November 4th. The company reported ($0.38) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.03. PROCEPT BioRobotics had a negative return on equity of 21.72% and a negative net margin of 28.20%.The firm had revenue of $83.33 million during the quarter, compared to the consensus estimate of $80.78 million. During the same period in the prior year, the company earned ($0.40) EPS. The company’s quarterly revenue was up 42.6% compared to the same quarter last year. PROCEPT BioRobotics has set its FY 2026 guidance at EPS. FY 2025 guidance at EPS. As a group, equities analysts anticipate that PROCEPT BioRobotics Corporation will post -1.75 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

PRCT has been the topic of a number of recent analyst reports. Leerink Partners reissued an “outperform” rating and set a $55.00 price target on shares of PROCEPT BioRobotics in a report on Wednesday, November 5th. Oppenheimer raised PROCEPT BioRobotics from a “market perform” rating to an “outperform” rating and set a $60.00 target price on the stock in a research note on Tuesday, September 2nd. Wells Fargo & Company dropped their price target on PROCEPT BioRobotics from $58.00 to $51.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. BTIG Research reiterated a “neutral” rating on shares of PROCEPT BioRobotics in a research report on Tuesday, September 16th. Finally, TD Cowen reduced their price objective on shares of PROCEPT BioRobotics from $85.00 to $50.00 and set a “buy” rating on the stock in a research report on Wednesday, November 5th. Nine analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $59.78.

PROCEPT BioRobotics Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).